Abstract
Stability of attenuating mutations is an important premise for live attenuated influenza vaccine (LAIV). The presence of multiple mutations in internal gene segments of live attenuated viruses contributes to the stability of their genomes and consistent phenotypic properties. This study describes the evaluation of results of clinical isolates obtained in Phase I clinical trials of three Russian LAIVs against potentially pandemic influenza viruses which may cause serious and fatal disease in humans. As part of clinical trials, nasal swabs were tested for vaccine virus shedding, for temperature sensitivity and cold–adaptation and for nucleotide sequence. Vaccine viruses isolated from the vaccinated subjects were shown to retain phenotypic characteristics and attenuating mutations. These data suggest genetic stability of vaccine virus after replication in humans. In addition, no vaccine virus was detected in the placebo groups indicating the lack of person–to–person transmission.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
